Trial reportPloS one2026
Effects of esketamine on postoperative pain, anxiety, depression, sleep, and inflammation in pregnancies undergoing cesarean section: A randomized controlled trial.
Trial report in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivePostoperative pain is the most notable issue after cesarean section (CS). The contributing factors include hyperalgesia, anxiety, depression, sleep disorders, and inflammation. In this study, we explored the effects of esketamine on pain, hyperalgesia, depression, anxiety, sleep disorders, and inflammation after CS.
methodsThis randomized, blinded, controlled trial enrolled single-term pregnant women scheduled for elective CS. This trial was a single-center study conducted at Chongqing University Fuling Hospital. A simple randomization method was used. SPSS version 26.0 generated random numbers. The participants were randomly included in the esketamine group (group E: intravenous esketamine 0.5 mg/kg + sufentanil 4 μg/kg followed by patient-controlled intravenous analgesia with esketamine 0.5 mg/kg) or the control group (C: normal saline + sufentanil 4 μg/kg PCIA). The primary outcome was the maximum pain numerical rating scale (NRS) score within 24 h postoperatively. The secondary outcomes included pain NRS scores for moving incision, visceral, and rest incision pain at 0-6 h, 6-12 h and 12-24 h; pressure pain threshold and tolerance at 30 min and 24 h postoperatively; PCIA drug consumption, number of compressions, and dosage of rescue analgesics; time to first PCIA compression; serum C-reactive protein (CRP) at 24 h; incidence of drug-related side effects; and rates of anxiety, depression, and sleep disorders on postoperative day 2.
resultsNinety-eight women were randomly included in group E (n = 50) or C (n = 48). Group E showed significantly lower maximum NRS pain scores within 24 h (5 [4-5] vs. 6 [5-6], P < 0.0001) and relieved rest incision, visceral, and moving incision pain at all time points. The PCIA compression was significantly delayed and CRP levels, as well as the incidence of postoperative depression, anxiety, and sleep disorders, were lower in group E. There were no statistically significant differences in hyperalgesia or side effects between the groups.
conclusionIntravenous esketamine could effectively reduce postoperative pain, psychological disorders, and inflammation after CS. This study was registered in the Chinese Clinical Trial Registry with registration number ChiCTR2300078310.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.